Literature DB >> 26045030

Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.

Tomohiro Tamura1, Katsunori Kagohashi, Hiroaki Satoh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26045030     DOI: 10.1159/000431351

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


× No keyword cloud information.
  4 in total

1.  Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.

Authors:  Hong Shi; Xiaoyan Zhang; Fei Wang; Daoming Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yitao Wan; Yuan Yuan; Yueyin Pan; Ying Zhang
Journal:  Exp Ther Med       Date:  2017-04-18       Impact factor: 2.447

3.  [Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis].

Authors:  Chang Liu; Lu Cai; Diansheng Zhong; Jing Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-01

Review 4.  Adenosquamous carcinoma of the lung.

Authors:  Chenghui Li; Hongyang Lu
Journal:  Onco Targets Ther       Date:  2018-08-14       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.